Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

2011 issue of the Journal of Biological Chemistry.
  • Expanded its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include the fields of addiction and compulsive disorders. Currently, Omeros is advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse and The Michael J. Fox Foundation.
  • Announced the identification of compounds that interact selectively with two orphan GPCRs linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now publicly announced that it has successfully unlocked five orphan GPCRs for drug development.
  • Reported positive results from the Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.  In this 221-patient study, subjects treated with OMS302 demonstrated statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure, and OMS302 significantly decreased (p=0.0418) pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). The product candidate was safe and well tolerated in this study.
  • Announced that OMS103HP failed to meet prespecified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery. The data were confounded, and Omeros could not determine whether a drug effect was present in these trials.

  • About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the cen
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/20/2014)... issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health Canada, ... mg/metered dose due to the product missing the "dip tube," ... A missing "dip tube" could pose a potential problem with ... lead patients to believe they are receiving the nitroglycerin, when ... nitroglycerin could place them at risk for either a delay ...
    (Date:9/19/2014)... , Sept. 19, 2014 Medical ... forging relationships with key opinion leaders (KOLs) who ... competition. Despite the critical nature of the MSL ... challenges, including altering the landscape for creating and ... According to research, the oversight responsibility for the ...
    (Date:9/19/2014)... Harwood Feffer LLP ( www.hfesq.com ) is ... PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... its fiduciary duties to shareholders or violated the federal ... Company disclosed: "On September 11, 2014, [PDL] was orally ... Young LLP ("EY"), that it was resigning effective September ...
    Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
    ... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the ... commercialization of its proprietary stent platform technology, today announced that ... ended September 30, 2011 with the U.S. Securities and Exchange ... Year-to-Date Highlights Year-to-date shipment ...
    ... The new harder to crush version of OxyContin® has ... research revealed at a conference of law enforcement officers ... Prevention (CDC) announced that every day 100 people die ... prescription opioid pain relievers. A new formulation of the ...
    Cached Medicine Technology:InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 2InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 3InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 4InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 5InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 6InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 7InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 8InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 9New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
    (Date:9/20/2014)... Ticket Down is a reputable source ... popular ticket exchange is offering their customer appreciation promo code ... next step in the entertainment business. The 21-year-old from Boca ... and entertainment business, but is closing in on “Pop Diva” ... album, will hit the road next year on the “Honeymoon ...
    (Date:9/20/2014)... 2014 On Monday, September 22, Loma ... cancer research grant from Hyundai Hope on Wheels at ... Hospital located on 11234 Anderson St., in Loma Linda. ... Payne, Associate Professor at Loma Linda University and Director ... in children. , Loma Linda University Medical ...
    (Date:9/20/2014)... York, New York (PRWEB) September 20, 2014 ... filings continue to grow in federal court, Bernstein ... Food & Drug Administration (FDA) have voted overwhelmingly ... low testosterone in men be subjected to further ... According to a report published on September 18th ...
    (Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
    (Date:9/20/2014)... 20, 2014 Lifeinsurancequoteterm.net has released ... no medical exam life insurance plan provides for vulnerable ... family members should be a top priority for every ... insurance without taking medical examinations and visiting a doctor. ... medical examinations will provide coverage up to $300,000, but ...
    Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2
    ... research led by a psychologist at the University of Georgia ... understanding of craving for alcohol and other drugs. This ... values a drug is fairly new, but according to the ... contribute to identifying more effective ways to defeat addictions. ...
    ... HealthDay Reporter , TUESDAY, July 13 (HealthDay News) ... survive the original cancer are at high risk of ... and stroke likely caused by the cancer treatment itself, ... cancer, many have long-term risks of dying prematurely from ...
    ... guidelines on recommended vitamin D intake have been published this ... Association Journal ( CMAJ ). Dr. David Hanley, ... member of Osteoporosis Canada,s (OC) Scientific Advisory Council, is the ... "OC,s current recommendations on vitamin D intake for Canadians ...
    ... By Amanda Gardner HealthDay Reporter , TUESDAY, ... the safety of controversial diabetes drug Avandia, members of the ... skeptical of much of the data presented. A decision ... The hearing has coincided with news that the drug,s ...
    ... regarding treatment following breast-conserving surgery for patients diagnosed with ... of discussion and confusion for patients and physicians alike. ... risk of local recurrence in the breast is high. ... treatment. While both treatments have been proven to ...
    ... protein already used to treat diseases like multiple sclerosis, hepatitis ... patients, UT Southwestern Medical Center researchers have found. ... of a population of immune cells known to cause asthma. ... called T helper 2 cells, or Th2 cells. Under normal ...
    Cached Medicine News:Health News:New analysis may help clarify the role of craving in addiction 2Health News:New analysis may help clarify the role of craving in addiction 3Health News:Childhood Cancer Survivors at Risk of Premature Death 2Health News:Childhood Cancer Survivors at Risk of Premature Death 3Health News:New vitamin D guidelines 2Health News:FDA Panel Seems Skeptical Over Key Avandia Data 2Health News:FDA Panel Seems Skeptical Over Key Avandia Data 3Health News:FDA Panel Seems Skeptical Over Key Avandia Data 4Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Interferon might help asthma patients breathe easier, UT Southwestern study suggests 2
    0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
    3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
    For use in implant arthroplasty associated with comminuted fractures, or rheumatoid, degenerative or post-traumatic disease of the radial head. Designed for higher demand patients requiring superior ...
    This legless table has adjustable height and round post. Pad sold separately....
    Medicine Products: